Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NUC-1010
- Development stage
- Phase 1
- Lead developer
- Nucorion Pharmaceuticals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
NUC-1010 is a preclinical-stage nucleotide analog being developed by Nucorion Pharmaceuticals for the treatment of chronic Hepatitis B virus (HBV) infection. The candidate is engineered using Nucorion's proprietary Liver Targeting Platform (LTP) technology, which is designed to maximize the concentration of the active nucleotide triphosphate within hepatocytes while minimizing systemic exposure and associated side effects. As a nucleotide analog, NUC-1010 is intended to inhibit viral replication by targeting the HBV polymerase/reverse transcriptase, although the specific molecular details of the compound remain proprietary. The program is currently in preclinical development, leveraging the LTP technology to improve the therapeutic index compared to existing nucleoside/nucleotide reverse transcriptase inhibitors.
- Other names
- tenofovir prodrug
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on NUC-1010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NUC-1010.